Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma
Jozefina Casuscelli(LMU Klinikum), A. Ari Hakimi(Penn State Milton S. Hershey Medical Center), Mahyar Kashan(Memorial Sloan Kettering Cancer Center), Victor E. Reuter(Memorial Sloan Kettering Cancer Center), Darren R. Feldman(Memorial Sloan Kettering Cancer Center), Almedina Redzematovic(Memorial Sloan Kettering Cancer Center), James J. Hsieh(Memorial Sloan Kettering Cancer Center), Paul Russo(Memorial Sloan Kettering Cancer Center), Maria E. Arcila(Memorial Sloan Kettering Cancer Center), Emily C. Zabor(Cleveland Clinic), Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Daniel Tennenbaum(Memorial Sloan Kettering Cancer Center), Christian G. Stief(LMU Klinikum), Mazyar Ghanaat(Memorial Sloan Kettering Cancer Center), Maria I. Carlo(Memorial Sloan Kettering Cancer Center), Jonathan Coleman(Memorial Sloan Kettering Cancer Center), Ed Reznik(Icahn School of Medicine at Mount Sinai), Martin H. Voss(Memorial Sloan Kettering Cancer Center), Ying‐Bei Chen(Memorial Sloan Kettering Cancer Center), Maria F. Becerra(Memorial Sloan Kettering Cancer Center), Brandon J. Manley(Moffitt Cancer Center)
Cited by 46
Related Papers
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Clinical-grade computational pathology using weakly supervised deep learning on whole slide images
|Nature Medicine|2019|2.6k